As Pfizer’s sales continue to struggle, they’ve turned to acquisitions as a means of making up for lost revenue. And one company they have their eye on is Seagen - a cancer drugmaker with a market cap of roughly $30 billion. Last year, Seagen was rumored to be acquired by Merck. This deal could [...]